CatalystMarker
← board

TRAW

Traws Pharma, Inc.distress 8/10 · high distress / dilution risk
$0.53-1%today-83% from 52w high
trawspharma.com4 employeesFounded 1998Newtown, PABiotechnology
Infectious Disease 1Oncology 1
Lead: COVID-19
Revenue
pre-revenue
Liquidity
$3M
Runway
0.2 yrs
Shares 1y
+115%

Price & events

-78.6% over 6M
$0.53$1.68$2.82Jan 26Apr 26Jul 2689.5Mdilution: 424B5 offering (2026-07-10)dilution: EFFECT shelf_effective (2026-07-09)dilution: S-3 shelf_registration (2026-07-01)dilution: 424B5 offering (2026-05-22)dilution: 424B3 offering (2026-05-15)dilution: EFFECT shelf_effective (2026-05-15)dilution: S-3 shelf_registration (2026-05-08)financing: 8-K private_placement (2026-04-15)catalyst: tivoxavir marboxil (2026-06-30) — click to opencatalyst: PHASE2 tivoxavir marboxil (2026-06-30) — click to opencatalyst: tivoxavir marboxil (2026-06-01) — click to opencatalyst: PHASE2 Ratutrelvir (83-0060) non-randomised, Paxlovid, Ratutrelvir (83-0060) (2026-02-01) — click to opencatalyst: PHASE2 ratutrelvir (2026-01-31) — click to opencatalyst: PHASE2 ratutrelvir (2026-01-31) — click to openrating: HC Wainwright & Co.: Buy → Neutral (2026-06-18)rating: Ladenburg Thalmann: Buy → Neutral (2026-06-15)rating: HC Wainwright & Co.: Buy (2026-05-20)
CatalystRating changeDilutionFinancingdashed = today
-1.1%
1D
-19.1%
1W
-36.4%
1M
-56.2%
3M
-77.9%
6M
-68.4%
1Y
-95.3%
2Y
-99.6%
5Y
-99.7%
All

Overview

Market Cap
$8.09M
Volume
10.86K
52 Week Range
$0.53 – $3.13
Total Shares
15.15M
Float Shares
11.73M
Short %
7.59%
% Held by Insiders
5.38%
% Held by Institutions
43.92%
RVOL
0.03x
Beta
1.51

Pipeline stages · 3 programs

TRX-100, Standard of Care (SOC)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2026-09
Ratutrelvir (83-0060) non-randomised, Paxlovid, Ratutrelvir (83-0060)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Narazaciclib, Letrozole 2.5mg
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved

Pipeline · 6 trials · 3 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
2026-09
Estimated 50%
readout ~2026-10-01
Phase 1TRX-100 or placeboHealthy Volunteer24recruiting
2026-11
Estimated 50%
readout ~2026-12-16
Phase 2TRX-100, Influenza A/France/759/2021 (H1N1) virusInfluenza—not yet recruiting
2026-12
Estimated 50%
readout ~2027-01-15
Phase 2TRX-100, Standard of Care (SOC)Influenza—active not recruiting
2026-02
Phase 2Ratutrelvir (83-0060) non-randomised, Paxlovid, Ratutrelvir (83-0060)COVID - 1990recruiting
2026-01
Phase 1/2Narazaciclib, Letrozole 2.5mgEndometrioid Endometrial Cancer60unknown
Show all 6 trials · 1 more ▾
ReadoutPhaseDrugIndicationEnrollStatus
2025-01-16
Phase 1TRX-100Healthy Volunteer Study66completed

Catalyst news & presentations · 10

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 15,150,669 · 3 offerings/1y · 1 PIPEs
  • 2026-07-10424B5offering
  • 2026-07-09EFFECTshelf_effective
  • 2026-07-01S-3shelf_registration
  • 2026-05-22424B5offering
  • 2026-05-15EFFECTshelf_effective
  • 2026-05-15424B3offering
  • 2026-05-08S-3shelf_registration
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

hold · target $1 (+87% upside) · 1 analysts
  • 2026-06-18HC Wainwright & Co.Buy → Neutral
  • 2026-06-15Ladenburg ThalmannBuy → Neutral
  • 2026-05-20HC Wainwright & Co.Buy
  • 2025-12-03HC Wainwright & Co.Buy

Competitors — COVID-19

  • MRKMerck & Co., Inc.$318.8B · D3
  • PFEPFIZER INC$142.2B · D3
  • BNTXBioNTech SE$23.1B · D1
  • NVAXNOVAVAX INC$1.3B · D3
  • OCGNOcugen, Inc.$423M · D7
  • ENTAENANTA PHARMACEUTICALS INC$373M · D5
  • ALGSAligos Therapeutics, Inc.$217M · D3
  • IVVDInvivyd, Inc.$180M · D4
  • VXRTVaxart, Inc.$121M · D4
  • GOVXGeoVax Labs, Inc.$3M · D6

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.